Trial Profile

A phase 3 study of the fixed dose combination (FDC) tablets of bemnifosbuvir and ruzasvir

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Sofosbuvir/velpatasvir
Indications Hepatitis C
Focus Registrational; Therapeutic Use
Acronyms C-FORWARD

Most Recent Events

23 Apr 2025 According to Atea Pharmaceuticals media release, enrollment of patients in this study is expected to begin Q2 2025.
14 Apr 2025 Planned number of patients changed from 800 to 880.
06 Mar 2025 According to Atea Pharmaceuticals media release, company is initiating the global Phase 3 program and expects patient enrollment to start in April 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com